

Arturo Molina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10946188/publications.pdf>

Version: 2024-02-01

91
papers

17,914
citations

38742

50
h-index

53230

85
g-index

91
all docs

91
docs citations

91
times ranked

11578
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. <i>European Urology</i> , 2019, 76, 418-424.	1.9	43
2	Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 72-77.e1.	1.9	24
3	Reply to C. Ren et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2354-2356.	1.6	0
4	Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 572-580.	1.6	187
5	The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population. <i>Clinical Cancer Research</i> , 2017, 23, 1967-1973.	7.0	46
6	Reply to A. Addeo and A. Bahl. <i>Journal of Clinical Oncology</i> , 2016, 34, 387-388.	1.6	0
7	Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. <i>European Urology</i> , 2016, 70, 985-992.	1.9	119
8	Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. <i>European Urology</i> , 2016, 69, 924-932.	1.9	22
9	Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302. <i>European Urology</i> , 2015, 68, 570-577.	1.9	50
10	Improvements in Radiographic Progression-Free Survival Stratified by <i>ERG</i> Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. <i>Clinical Cancer Research</i> , 2015, 21, 1621-1627.	7.0	51
11	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 152-160.	10.7	1,100
12	Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. <i>Journal of Clinical Oncology</i> , 2015, 33, 1356-1363.	1.6	120
13	Impact of Baseline Corticosteroids on Survival and Steroid Androgens in Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis from COU-AA-301. <i>European Urology</i> , 2015, 67, 866-873.	1.9	49
14	Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2015, 194, 1277-1284.	0.4	65
15	Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1348-1355.	1.6	343
16	Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens. <i>Clinical Cancer Research</i> , 2014, 20, 6269-6276.	7.0	32
17	Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 732-741.	2.0	26
18	Response to Subsequent Docetaxel in a Patient Cohort With Metastatic Castration-Resistant Prostate Cancer After Abiraterone Acetate Treatment. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e167-e172.	1.9	32

#	ARTICLE	IF	CITATIONS
19	Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3705-3715.	1.6	220
20	Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. <i>Lancet Oncology</i> , The, 2014, 15, 1263-1268.	10.7	46
21	Efficacy and Safety of Abiraterone Acetate in an Elderly Patient Subgroup (Aged 75 and Older) with Metastatic Castration-resistant Prostate Cancer After Docetaxel-based Chemotherapy. <i>European Urology</i> , 2014, 65, 875-883.	1.9	74
22	Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). <i>European Urology</i> , 2014, 66, 815-825.	1.9	221
23	Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1193-1199.	10.7	142
24	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. <i>New England Journal of Medicine</i> , 2013, 368, 138-148.	27.0	2,412
25	Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. <i>European Journal of Cancer</i> , 2013, 49, 3648-3657.	2.8	77
26	Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 2791-2798.	1.6	111
27	Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-Type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100. <i>Cancer Research</i> , 2013, 73, 2926-2926.	0.9	5
28	Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine. <i>International Journal of Oncology</i> , 2013, 43, 670-676.	3.3	9
29	A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel. <i>Journal of Clinical Oncology</i> , 2013, 31, 5013-5013.	1.6	12
30	Effect of abiraterone acetate (AA) on patient-reported pain in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel: Results of longitudinal sensitivity analyses. <i>Journal of Clinical Oncology</i> , 2013, 31, 9618-9618.	1.6	2
31	Fast and Flawed or Scientifically Sound: The Argument for Administering Oral Oncology Drugs During Fasting. <i>Journal of Clinical Oncology</i> , 2012, 30, 888-889.	1.6	13
32	Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone. <i>Journal of Clinical Oncology</i> , 2012, 30, 637-643.	1.6	168
33	Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2012, 13, 983-992.	10.7	1,182
34	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 1210-1217.	10.7	254
35	Abstract 3635: Association of reduction in serum androgens and change in serum PSA in patients treated with abiraterone acetate (AA): A subset analysis of the COU-AA-301 phase 3 randomized trial. , 2012, , .		2
36	Inhibition of B-NHL Tumor Xenografts Following Treatment with Galiximab (Anti-CD80 mAb) and Potentiation When Combined with Chemotherapy. <i>Blood</i> , 2012, 120, 4873-4873.	1.4	7

#	ARTICLE	IF	CITATIONS
37	Abiraterone and Increased Survival in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 1995-2005.	27.0	3,736
38	Novel Therapeutic Strategies for Castration Resistant Prostate Cancer: Inhibition of Persistent Androgen Production and Androgen Receptor Mediated Signaling. <i>Journal of Urology</i> , 2011, 185, 787-794.	0.4	98
39	TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate. <i>European Urology</i> , 2011, 60, 897-904.	1.9	176
40	Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response. <i>Clinical Cancer Research</i> , 2011, 17, 4854-4861.	7.0	203
41	Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. <i>Blood</i> , 2010, 115, 489-495.	1.4	86
42	Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate. <i>Journal of Clinical Oncology</i> , 2010, 28, 1489-1495.	1.6	370
43	Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 1481-1488.	1.6	369
44	Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1496-1501.	1.6	396
45	Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3742-3748.	1.6	545
46	Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1653-1659.	1.6	101
47	Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: Long-Term Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 554-563.	2.0	33
48	Characterization of <i>ERG</i> , <i>AR</i> and <i>PTEN</i> Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2009, 69, 2912-2918.	0.9	518
49	A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma. <i>Annual Review of Medicine</i> , 2008, 59, 237-250.	12.2	174
50	Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 90-95.	1.6	150
51	Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. <i>Blood</i> , 2008, 111, 1594-1602.	1.4	70
52	Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 4285-4292.	1.6	142
53	Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2007, 13, 4448-4455.	7.0	101
54	Use of Radioimmunotherapy in Stem Cell Transplantation and Posttransplantation: Focus on Yttrium 90 Ibritumomab Tiuxetan. <i>Current Stem Cell Research and Therapy</i> , 2007, 2, 239-248.	1.3	8

#	ARTICLE	IF	CITATIONS
55	Safety and Efficacy of Yttrium-90 Ibritumomab Tiuxetan in Older Patients With Non-Hodgkin's Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 684-691.	1.0	35
56	Weight-Based Dosing of Yttrium 90 Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 514-517.	1.4	7
57	Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. <i>Cancer</i> , 2007, 109, 1804-1810.	4.1	164
58	Updated Results of High-Dose Yttrium 90 (90Y) Ibritumomab Tiuxetan with High-Dose Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Autologous Hematopoietic Cell Transplant (AHSCT) for Poor-Risk or Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2007, 110, 1891-1891.	1.4	8
59	Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 629-636.	1.3	83
60	Does Follicularity in Large Cell Lymphoma Predict Outcome after Autologous Stem Cell Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 641-647.	2.0	10
61	A Comparison of Beam and Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) in Addition to Beam (Z-BEAM) in Older Patients Undergoing Autologous Stem Cell Transplant (ASCT) for B-Cell Lymphomas: Impact of Radioimmunotherapy on Transplant Outcomes. <i>Blood</i> , 2006, 108, 3043-3043.	1.4	7
62	Comparison of Results from a Phase 1/2 Study of Lumiliximab (Anti-CD23) in Combination with FCR for Patients with Relapsed CLL with Published FCR Results. <i>Blood</i> , 2006, 108, 32-32.	1.4	19
63	90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL. <i>Blood</i> , 2006, 108, 330-330.	1.4	12
64	Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. <i>Blood</i> , 2005, 105, 874-878.	1.4	187
65	A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. <i>Blood</i> , 2005, 106, 2896-2902.	1.4	199
66	Clinical Studies of Immunotherapy With Rituximab (Rituxan®) and Radioimmunotherapy With Ibritumomab Tiuxetan (Zevalin®) in B-Cell Lymphoid Malignancies. , 2005, , 677-709.		0
67	Durable Clinical, Cytogenetic, and Molecular Remissions After Allogeneic Hematopoietic Cell Transplantation for Refractory Sezary Syndrome and Mycosis Fungoides. <i>Journal of Clinical Oncology</i> , 2005, 23, 6163-6171.	1.6	134
68	Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. <i>Blood</i> , 2004, 103, 4429-4431.	1.4	181
69	Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune Diseases. <i>Annual Review of Medicine</i> , 2004, 55, 477-503.	12.2	203
70	Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma and Mild Thrombocytopenia. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 478-481.	1.0	27
71	Yttrium 90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 98-101.	2.1	117
72	Antilymphoma Treatments Given Subsequent to Yttrium 90 Ibritumomab Tiuxetan Are Feasible in Patients with Progressive Non-Hodgkin's Lymphoma: A Review of the Literature. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 202-204.	2.1	37

#	ARTICLE	IF	CITATIONS
73	Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. <i>Blood</i> , 2004, 104, 3797-3803.	1.4	108
74	Evaluation of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Non-Hodgkin's Lymphoma (NHL) Having Previously Received Autologous Stem Cell Transplant (ASCT).. <i>Blood</i> , 2004, 104, 5238-5238.	1.4	1
75	Autologous vs Allogeneic Cell Transplantation for Mantle Cell Lymphoma (MCL): Outcomes over a 10-Year Period at City of Hope.. <i>Blood</i> , 2004, 104, 894-894.	1.4	5
76	Evaluation of Baseline Body-Weight Dosing of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).. <i>Blood</i> , 2004, 104, 2634-2634.	1.4	0
77	Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Responses in Patients with Relapsed or Refractory Follicular Lymphoma (FL).. <i>Blood</i> , 2004, 104, 2629-2629.	1.4	0
78	Treatment of human immunodeficiency virus-related lymphoma with haematopoietic stem cell transplantation. <i>Blood Reviews</i> , 2003, 17, 249-258.	5.7	13
79	Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. <i>Blood</i> , 2003, 102, 3521-3529.	1.4	339
80	Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2001, 19, 376-388.	1.6	615
81	CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenström's Macroglobulinemia. <i>Journal of Immunotherapy</i> , 2001, 24, 272-279.	2.4	144
82	Autologous stem cell transplantation for HIV-associated lymphoma. <i>Blood</i> , 2001, 98, 3857-3859.	1.4	87
83	Autologous stem cell transplantation for HIV-associated lymphoma. <i>Blood</i> , 2001, 98, 3857-3859.	1.4	7
84	High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. <i>Cancer</i> , 2000, 89, 680-689.	4.1	58
85	Acute Postoperative Dermatitis at the Site of the Electrocautery Pad: Sweet Diagnosis of a Burning Issue. <i>Surgery Today</i> , 2000, 30, 0207-0209.	1.5	5
86	Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. <i>Blood</i> , 2000, 95, 1588-1593.	1.4	270
87	Autologous Stem-Cell Transplantation for Poor-Risk and Relapsed Intermediate- and High-Grade Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2000, 1, 46-54.	2.1	49
88	Remission of refractory Sezary syndrome after bone marrow transplantation from a matched unrelated donor. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 400-404.	2.0	47
89	Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and High-Intermediate Risk Group. <i>Blood</i> , 1997, 90, 3844-3852.	1.4	93
90	A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer. <i>Cancer</i> , 1991, 67, 2253-2257.	4.1	19

#	ARTICLE	IF	CITATIONS
91	Immunohistochemical and cytogenetic studies indicate that malignant angioendotheliomatosis is a primary intravascular (angiotropic) lymphoma. <i>Cancer</i> , 1990, 66, 474-479.	4.1	82